Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ciphergen Biosystems Inc..

This article was originally published in Start Up

Executive Summary

Ciphergen Biosystems believes it has technology that is to proteins what PCR was to DNA. The start-up's technology uses silicon chips to help researchers capture proteins and look at the molecules in whatever state they prefer--either bound up in complexes or in increasingly purified forms.

You may also be interested in...

Bringing the Ovarian Cancer Test to Market

An ovarian cancer assay based on protein pattern analysis is arousing excitement in a field all too often met with disappointment. Given initial excitement over the test and protein pattern analysis in general, business activity is likely to follow shortly. The NCI, FDA and a start-up, Correlogic Systems, are developing the test and taking it to large clinical trials this summer. Correlogic claims to have broad patents on pattern analysis for diagnostic purposes, a contention that is sure to lead to controversy, given the apparently high stakes.

Proteomics: Business or Add-On?

Advocates of proteomics argue that without an understanding of protein interactions, drug researchers will be attempting to paint Old Masters with an incomplete set of genomic paint-by-number instructions.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts